[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group name:Otilimab Type of group;1 N\u00b0 of participants:400 Intervention(s) description:Participants receive a blinded 1-hour infusion of Otilimab 90 mg IV in addition to standard of care.\t\t\t\tGroup name:Otilimab placebo Type of group;2 N\u00b0 of participants:400 Intervention(s) description:Participants receive a blinded 1-hour infusion of Otilimab placebo 90 mg IV in addition to standard of care.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 940, "treatment_name": "Otilimab", "treatment_type": "Monoclonal antibodies", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]

[]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group name:Otilimab Type of group;1 N\u00b0 of participants:400 Intervention(s) description:Participants receive a blinded 1-hour infusion of Otilimab 90 mg IV in addition to standard of care.Group name:Otilimab placebo Type of group;2 N\u00b0 of participants:400 Intervention(s) description:Participants receive a blinded 1-hour infusion of Otilimab placebo 90 mg IV in addition to standard of care.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]